Market Place
Sourcing Support
Prilenia to Present Pridopidine Data at Huntington Study Group 2024
05 Nov 2024 //
BUSINESSWIRE
Prilenia Appoints Rob Lauzen As Chief Financial Officer
19 Sep 2024 //
BUSINESSWIRE
Prilenia`s Pridopidine Accepted for European Review for Huntington`s Disease
03 Sep 2024 //
BUSINESSWIRE
Prilenia: Huntington`s, ALS Pridopidine Data At AAN 2024
12 Apr 2024 //
BUSINESSWIRE
Prilenia Plans to Submit MAA in the EU for Pridopidine in Huntington’s Disease
12 Mar 2024 //
BUSINESSWIRE
Prilenia Announces Data in Support of Plans to Initiate Phase 3 Study in ALS
19 Jan 2024 //
BUSINESSWIRE
Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study
28 Mar 2023 //
BUSINESSWIRE
Prilenia Announces Topline Results for Pridopidine in Phase 2 ALS Study
23 Feb 2023 //
BUSINESSWIRE
Prilenia searches for positive signs in phase 2 ALS fail
23 Feb 2023 //
FIERCE BIOTECH
Prilenia Expands Leadership Team, Appoints Anne Sullivan as CBO
29 Sep 2022 //
BUSINESSWIRE
Prilenia Completes Enrollment Ahead of Schedule in HEALEY ALS Platform Trial
05 Jan 2022 //
BUSINESSWIRE
Prilenia Receives FTD for Pridopidine for Huntington’s Disease
17 Nov 2021 //
BUSINESSWIRE
Going after Huntington`s disease again, ex-Teva R&D chief gets cash for Prilenia
04 Nov 2021 //
ENDPTS
Prilenia Closes Oversubscribed $43 Million in Series B Financing Round
03 Nov 2021 //
PRESS RELEASE
Prilenia and Huntington Study Group Announce Completion of Patient Enrollment
20 Oct 2021 //
BUSINESSWIRE
Prilenia’s Phase 3 Huntington’s Disease Clinical Trial Achieves 50% Enrollment
07 Jul 2021 //
BUSINESSWIRE
Prilenia`s positive EMA opinion on Orphan Drug Designation for pridopidine
29 Jun 2021 //
BUSINESSWIRE
Prilenia`s pridopidine receives positive EMA opinion on Orphan Drug Designation
29 Jun 2021 //
BUSINESSWIRE
Prilenia Achieves 25% in its Phase 3 HD Trial and Appoints Dr. Goldberg as CSO
13 May 2021 //
BUSINESSWIRE
Prilenia Enrolls First Subject in Europe in its PROOF-HD Phase 3 Clinical Trial
28 Jan 2021 //
BIOSPACE
Prilenia Announces First Patient Enrolled for Pridopidine Phase 2/3 Platform
08 Jan 2021 //
BUSINESSWIRE
Prilenia Announces First Patient Enrolled for Pridopidine Ph2/3 Platform
08 Jan 2021 //
BUSINESSWIRE
Prilenia Enrolls First Patients Into its PROOF-HD Phase 3 Clinical Trial
27 Oct 2020 //
BIOSPACE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.